Welcome to our dedicated page for PUMA BIOTECHNOLOGY news (Ticker: PBYI), a resource for investors and traders seeking the latest updates and insights on PUMA BIOTECHNOLOGY stock.
Puma Biotechnology reports developments for a biopharmaceutical company built around oncology drug commercialization and development. Company news commonly centers on NERLYNX®, its oral neratinib product for HER2-positive breast cancer, including net product revenue, cost of sales, royalty revenue and financial outlook tied to demand for the therapy.
Updates also cover alisertib, a selective, orally administered aurora kinase A inhibitor licensed for development and commercialization. Puma describes the ALISCA™-Lung1 Phase II trial in extensive-stage small cell lung cancer and the ALISCA™-Breast1 Phase II trial in HER2-negative, HR-positive metastatic breast cancer, along with employee inducement equity awards under Nasdaq Listing Rule 5635(c)(4) and investor conference activity.
Puma Biotechnology (PBYI) has initiated ALISCA®-Lung2, a Phase II trial of alisertib in combination with paclitaxel for patients with advanced small cell lung cancer who have progressed after platinum-based chemotherapy and immunotherapy.
The sequential dose escalation study will enroll approximately 50 patients. The primary endpoint is the safety and tolerability of alisertib with paclitaxel. Secondary endpoints include objective response rate, duration of response, disease control rate, progression-free survival and overall survival. Puma will also evaluate clinical biomarkers to help identify patients most likely to benefit and to guide further development of alisertib. The company continues to advance alisertib monotherapy in the ALISCA®-Lung1 trial and views ALISCA®-Lung2 as additive to this program.
Puma Biotechnology (PBYI) will present at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026, at 3:30 p.m. ET. Chairman, Chief Executive Officer, President and Founder Alan H. Auerbach will provide an overview of Puma. The conference runs September 14–16, 2026, at the Lotte New York Palace Hotel in New York City. A live webcast and presentation slides will be available via the Investors section of Puma Biotechnology’s website, with the presentation archived online for 30 days.
Puma Biotechnology (PBYI) granted inducement restricted stock unit (RSU) awards covering 33,550 shares of common stock to five new non-executive employees, effective September 1, 2026.
The awards were made under Puma’s 2017 Employment Inducement Incentive Award Plan and are intended as inducements to employment in line with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over three years: one-third of the shares on the first anniversary of the September 1, 2026 vesting commencement date, and one-sixth of the shares on each six-month anniversary thereafter, subject to continued service.
Puma Biotechnology (NASDAQ:PBYI) reported second quarter 2026 total revenue of $56.5 million, up from $52.4 million a year earlier, driven by NERLYNX net product revenue of $53.6 million versus $49.2 million. GAAP net income was $8.2 million, or $0.16 per basic and diluted share, compared with $5.9 million, or $0.12 per share, in 2025. Non-GAAP adjusted net income was $10.1 million, or $0.20 per basic share.
For the first six months of 2026, total revenue reached $101.3 million and GAAP net income was $4.4 million, down from $8.8 million in 2025, reflecting higher R&D spending. Puma fully repaid its 2021 notes in May 2026, eliminating debt, and ended the quarter with $93.9 million in cash, cash equivalents and marketable securities.
Based on increased NERLYNX demand, Puma raised its full-year 2026 guidance, now expecting net product revenue of $205–$209 million, total revenue of $224–$231 million and net income of $17–$20 million. The company is also advancing its ALISCA alisertib clinical trials in breast and small cell lung cancer with several expansion and data milestones targeted through 2026.
Puma Biotechnology (NASDAQ: PBYI) reported that its Board’s Compensation Committee approved inducement restricted stock unit (RSU) awards covering 35,375 shares/b) of common stock for five new non-executive employees, effective August 3, 2026.The RSUs were granted under Puma’s 2017 Employment Inducement Incentive Award Plan and will vest over three years: one-third of the shares vest on August 1, 2027, and one-sixth of the shares vest on each six-month anniversary thereafter, subject to continued service. The awards are intended as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology (NASDAQ: PBYI) will host a conference call on Thursday, August 6, 2026, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its second quarter 2026 financial results. Investors can join via domestic dial-in 1-877-709-8150, international dial-in 1-201-689-8354, or a live webcast with slides on the Investors section of the company’s website. A replay will be available about one hour after the call and archived online for 90 days.
Puma Biotechnology (NASDAQ:PBYI) approved inducement restricted stock unit awards for four new non-executive employees under its 2017 Employment Inducement Incentive Award Plan.
The awards cover 31,625 shares of common stock and vest over three years, structured to comply with Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology (NASDAQ:PBYI) reported inducement restricted stock unit awards under Nasdaq Listing Rule 5635(c)(4). On June 1, 2026, the compensation committee granted RSU awards covering 7,000 shares of common stock to two new non-executive employees under Puma’s 2017 Employment Inducement Incentive Award Plan.
The RSUs vest over three years: one-third on June 1, 2027, then one-sixth every six months, subject to continued service.
Puma Biotechnology (NASDAQ: PBYI) reported Q1 2026 results and raised 2026 guidance after increased demand for NERLYNX. Q1 product revenue was $42.0M; GAAP net loss was $3.8M (‑$0.07/share). Puma raised full‑year 2026 revenue to $222–$229M and net income to $16–$19M. Cash and marketable securities were $101.5M at March 31, 2026; debt was reduced to zero after a May 4, 2026 final payment.
Management cited interim ALISCA™ trial data and outlined H2 2026 enrollment expansions and a Q4 2026 data presentation.
Puma Biotechnology (NASDAQ: PBYI) announced on May 5, 2026 that its Compensation Committee approved inducement restricted stock unit awards covering 59,750 shares to six new non-executive employees under the 2017 Employment Inducement Incentive Award Plan.
The RSUs vest over three years: one-third on the first anniversary of the vesting commencement date (May 1, 2026) and one-sixth every six months thereafter, subject to continued service, and were granted pursuant to Nasdaq Listing Rule 5635(c)(4).